M. Tsuboi
National Cancer Center Hospital East · 29 works · 148 citations · h-index 5
Top works
- LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
- OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC
- LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)
- LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671
- LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA
- OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC
- P3.18.09 SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy
- 1208MO Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study
- 270TiP Olomorasib and immunotherapy in stage II-III KRAS G12C-mutant NSCLC after definitive therapy: SUNRAY-02 study rationale
- OA12.04 Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT Trial (WJOG 12119L)
- OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
- 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
- LBA9 Perioperative pembrolizumab in early-stage non–small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup
- Current Status and Prospects of Perioperative Treatment with Immune Checkpoint Inhibitors for Resectable Non-Small Cell Lung Cancer
- MA10.04 Long-term Follow-up Study of Thymic Epithelial Tumors. Report of the Updated Nation-wide Database in Japan
- 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study
- 211P: Five-year survival outcomes from PIT-2: S-1 plus cisplatin with concurrent radiotherapy followed by surgery in stage IIIA (N2) lung squamous cell carcinoma
- Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
- 1015P Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small cell lung cancer after disease progression on platinum-based therapy: WJOG10317L study (EMERALD)
- 903MO Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in patients (pts) with resectable epidermal growth factor receptor-mutated (EGFRm) stage II–IIIB non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from NeoADAURA